Zydus Cadila receives tentative approval for Sitagliptin and Metformin Hydrochloride Tablets

FRom USFDA

Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Tablets in the strengths of 50 mg/ 500 mg and 50 mg/ 1000 mg.

This is a fixed dose combination of two anti-diabetic drugs indicated for Type II diabetes mellitus and will be produced at the group's formulations manufacturing facility at Pharma SEZ in Ahmedabad.

Powered by Capital Market - Live News